ceralasertib

News

AstraZeneca has had a setback in its oncology pipeline, as AKT inhibitor ceralasertib fails to improve survival in a phase 3 lung cancer trial.

News

In a busy week, the FDA granted two De Novo authorisations for consumer health devices and is rumoured to be mulling structural leadership changes.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.